Evidence map›Paper›PMID 24447817›Full record

ArticleJournal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)2014

Characterization of a monoclonal antibody capable of reliably quantifying expression of human Copper Transporter 1 (hCTR1).

Jacob F Quail, Cheng-Yu Tsai, Stephen B Howell

Abstract read
In one paragraph

Article in Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jacob F QuailMoores UCSD Cancer Center, University of California, San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093, United States.
Cheng-Yu TsaiMoores UCSD Cancer Center, University of California, San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093, United States.
Stephen B HowellMoores UCSD Cancer Center, University of California, San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093, United States. Electronic address: showell@ucsd.edu.
University of California, San Diego · US

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
Cisplatin Resistance mediated by copper export pathwaysR01CA095298 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HOWELL, STEPHEN B · 2002 to 2014
$3.1M
Control of the cellular pharmacology of the platinum-containing drugs by CTR1R01CA152185 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HOWELL, STEPHEN B · 2010 to 2014
$1.5M
NCI NIH HHS CA095298NCI NIH HHS CA152185NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA095298NCI NIH HHS R01 CA152185NCI NIH HHS T32 CA121938
6 · The paper itself

Abstract

Human copper transporter 1 (hCTR1) is the high-affinity copper influx transporter in mammalian cells that also mediates the influx of cisplatin. Loss of hCTR1 expression has been implicated in the development of resistance to this cancer chemotherapeutic agent. It has turned out to be very difficult to develop antibodies to hCTR1 and polyclonal antibodies produced by different laboratories have yielded conflicting results. We have characterized a newly-available rabbit monoclonal antibody that reacts with an epitope on the N-terminal end of hCTR1 that now permits rigorous identification and quantification of hCTR1 using Western blot analysis. Postnuclear membrane (PNM) preparations made from cells engineered to express high levels of myc-tagged hCTR1, and cells in which the expression of hCTR1 was knocked down, were used to characterize the antibody. The identity of the bands detected was confirmed by immunoprecipitation, surface biotinylation and deglycosylation of myc-tagged hCTR1. Despite the specificity expected of a monoclonal antibody, the anti-hCTR1 detected a variety of bands in whole cell lysates (WCL), which made it difficult to quantify hCTR1. This problem was overcome by isolating post-nuclear membranes and using these for further analysis. Three bands were identified using this antibody in PNM preparations that migrated at 28, 33-35 and 62-64kDa. Multiple lines of evidence presented here suggest that the 33-35 and 62-64kDa bands are hCTR1 whereas the 28kDa band is a cross-reacting protein of unknown identify. The 33-35kDa band is consistent with the expected MW of the glycosylated hCTR1 monomer. This analysis now permits rigorous identification and quantification of hCTR1.

Indexed as

Antibodies, MonoclonalBiotinylationBlotting, WesternCation Transport ProteinsCell ExtractsCell Line, TumorCell MembraneCisplatinCopper Transporter 1Down-RegulationGene Knockdown TechniquesGenetic EngineeringGlycosylationHEK293 CellsHumansImmunoprecipitationAntibodies, MonoclonalCation Transport ProteinsCell ExtractsCisplatinCopper Transporter 1CopperCopper transporter 1Monoclonal antibodyTransporterWestern blot

Identifiers

PMID24447817
PMCPMC3989404
OpenAlexW1977587453

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.